Page last updated: 2024-08-25

cholest-5-ene-3,4-diol and omeprazole

cholest-5-ene-3,4-diol has been researched along with omeprazole in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Andersson, TB; Bäckström, T; Bertilsson, L; Böttiger, Y; Bredberg, E; Diczfalusy, U; Kanebratt, KP; Sparve, E	1
Aklillu, E; Aminy, A; Bijnsdorp, A; Diczfalusy, U; Engidawork, E; Gebeyehu, E	1
Krishna, G; LoRusso, PM; Ogasawara, K; Olszanski, AJ; Palmisano, M; Rixe, O; Xu, C; Yin, J	1

Trials

2 trial(s) available for cholest-5-ene-3,4-diol and omeprazole

Article	Year
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:5 Topics: Adult; Anti-Ulcer Agents; Antibiotics, Antitubercular; Antihypertensive Agents; Antimalarials; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 Enzyme System; Drug Combinations; Enzyme Induction; Female; Humans; Hydroxycholesterols; Losartan; Male; Middle Aged; Omeprazole; Quinine; Rifampin	2008
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Male; Metoprolol; Midazolam; Middle Aged; Neoplasms; Omeprazole; Protein Kinase Inhibitors; Pyrrolidines; Sulfonamides	2020

Article

Year

Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.

Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:5

Topics: Adult; Anti-Ulcer Agents; Antibiotics, Antitubercular; Antihypertensive Agents; Antimalarials; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 Enzyme System; Drug Combinations; Enzyme Induction; Female; Humans; Hydroxycholesterols; Losartan; Male; Middle Aged; Omeprazole; Quinine; Rifampin

2008

Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.

Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:1

Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Male; Metoprolol; Midazolam; Middle Aged; Neoplasms; Omeprazole; Protein Kinase Inhibitors; Pyrrolidines; Sulfonamides

2020

Other Studies

1 other study(ies) available for cholest-5-ene-3,4-diol and omeprazole

Article	Year
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. The pharmacogenomics journal, 2011, Volume: 11, Issue:2 Topics: Adult; Alleles; Black People; Cholesterol; Cytochrome P-450 CYP3A; Ethiopia; Female; Genetic Variation; Genotype; Humans; Hydroxycholesterols; Male; Omeprazole; Sex Factors; Young Adult	2011